Factor X Deficiency (Stuart-Prower Factor Deficiency, FX)

Confirm the defect before you plan around it - a PT and aPTT that are both prolonged and both correct on a mixing study point at the common pathway; a factor X activity assay gives the number that drives replacement.

Correct with the right product - plasma-derived factor X concentrate is the targeted therapy. Four-factor PCC (II, VII, IX, X) is the fast alternative and runs roughly 25 times the clotting-factor concentration of plasma, so one dose replaces 8 to 16 units of FFP in a fraction of the volume. FFP works for isolated factor X deficiency when neither concentrate is stocked.

PCC is not free - higher doses raise thromboembolic risk, there is no antidote, and postmarketing reports include MI, TIA, arterial thrombosis, angioedema and bronchospasm. Dose to the deficit, not to the biggest vial on the shelf.

Give vitamin K with the concentrate when a VKA is in play - warfarin blocks vitamin K-dependent synthesis of II, VII, IX and X, and its half-life outlasts PCC. Vitamin K is what keeps the correction from unwinding a few hours into the case.

Hunt the acquired cause - in AL amyloidosis, periorbital purpura with a prolonged PT and aPTT that corrects on mixing is the tell. Severe amyloid-associated factor X deficiency with splenomegaly is sometimes managed with splenectomy, so ask whether that has happened before you interpret the counts.

Neuraxial - do not place until a factor X level is documented as corrected and hematology and surgery are on the same page. If it is not corrected, plan GETA and, if a block is worth doing, pick a superficial compressible site.

Big-loss preparation - type and screen early, have the concentrate physically in the room before incision rather than in the pharmacy, and check a post-replacement level rather than assuming the calculated dose landed.

Factor X is the convergence point of the coagulation cascade. Both tenase complexes feed into it — extrinsic (VIIa plus tissue factor) and intrinsic (VIIIa/IXa) — and once activated, Xa uses factor V as a cofactor to cleave prothrombin into thrombin. It is a vitamin K-dependent serine protease made in hepatocytes, so it sits downstream of everything and its deficiency prolongs both the PT and the aPTT, correcting on a mixing study.

Congenital deficiency is rare and, like most rare factor deficiencies, autosomal recessive; severe disease bleeds like severe hemophilia, with hemarthrosis and intracranial hemorrhage. Acquired deficiency is what you are more likely to meet: AL amyloidosis (2.5% of AL patients, classically with periorbital purpura), warfarin, vitamin K deficiency, and liver failure all cut factor X.